Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-3789 in open-angle glaucoma
NCT00643669Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2008
- Primary completion
- Apr 2008
- Countries
- 1
- Sponsor
- Alcon Inc.
- Modality
- Orthosteric Ligands
- Drugs
- anecortave
- Conditions
- open-angle glaucoma (OAG)
01
Overview
Phase 2, randomised, open-label trial of anecortave in open-angle glaucoma (OAG) (2 arms), sponsored by Alcon Inc. Primary endpoint: Mean Intraocular Pressure at Day 28. Started Feb 2008; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
AL-3789
Single depot administration of AL-3789
No treatment
Fellow eye, untreated control
03
Who it enrols
Patients with open-angle glaucoma treated with a topical prostaglandin analog for at least 30 days prior to screening.
04
Endpoints
Primary
Mean Intraocular Pressure
Beyond the preview
Go deeper on NCT00643669.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00643669.